All In Biotech

Free tool

FDA Approval Tracker

Original approvals of brand-name drugs and biologics (NDAs and BLAs) and efficacy supplements, which add a new use, population or dose. Approvals by CBER (most vaccines, blood products and cell and gene therapies) are not in Drugs@FDA and so are missing.

Last checked: Nov 20, 2026Latest source record: May 22, 2026Drugs@FDA last updated: Nov 18, 2026Methods & limitations

Reset

Matching approvals

153

2012 to 2026

Breakthrough

74

Accelerated

153

Priority review

131

Orphan

121

By year

NDAs and BLAs matching the filters.

  • NDA
  • BLA
View as table
YearNDABLA
201271
201340
201463
201572
201652
201755
201881
201973
2020137
2021116
202254
202366
202474
202585
202623

153 approvals

Newest first. Hover a badge for what it means.

  • Hepcludex (Bulevirtide-Gmod) · Gilead Sciences INCMay 22, 2026
    Original approval · BLA 761468NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter

    To treat chronic hepatitis delta virus infection in adults without cirrhosis or with compensated cirrhosis

  • Beqalzi (Sonrotoclax) · Beone Medicines USAMay 13, 2026
    Original approval · NDA 220711NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter

    To treat adults with relapsed or refractory mantle cell lymphoma after at least two lines of systemic therapy, including a Bruton's tyrosine kinase inhibitor

  • Avlayah (Tividenofusp Alfa-Eknm) · Denali Therapeutics Inc.Mar 24, 2026
    Original approval · BLA 761485NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter

    To treat certain individuals with Hunter syndrome (Mucopolysaccharidosis type II or MPS II)

  • Yuviwel (Navepegritide) · AscendisFeb 27, 2026
    Original approval · NDA 219164NovelAccelerated approvalPriority reviewOrphanApproval letter

    To increase linear growth in pediatric patients 2 years and older with achondroplasia with open epiphyses

  • Loargys (Pegzilarginase-Nbln) · Immedica Pharma AbFeb 23, 2026
    Original approval · BLA 761211NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter

    To treat hyperarginemia in adults and pediatric patients two years and older with Arginase 1 Deficiency, in conjunction with dietary protein restriction

  • Voyxact (Sibeprenlimab-Szsi) · Otsuka Pharm CO LTDNov 25, 2025
    Original approval · BLA 761434NovelBreakthrough therapyAccelerated approvalPriority reviewApproval letter

    To reduce proteinuria in primary immunoglobulin A nephropathy in adults at risk for disease progression

  • Hyrnuo (Sevabertinib) · Bayer HealthcareNov 19, 2025
    Original approval · NDA 219972NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter

    To treat locally advanced or metastatic non-squamous non-small cell lung cancer with tumors that have activating HER2 tyrosine kinase domain activating mutations in patients who received a systemic therapy

  • Keytruda Qlex (Pembrolizumab, Berahyaluronidase Alfa-Pmph) · Merck Sharp DohmeSep 19, 2025
    Original approval · BLA 761467NovelAccelerated approvalPriority reviewApproval letter

    To treat adult and pediatric (12 years and older) solid tumor indications approved for the intravenous formulation of pembrolizumab

  • Forzinity (Elamipretide Hydrochloride) · Stealth BiotherapsSep 19, 2025
    Original approval · NDA 215244NovelAccelerated approvalPriority reviewOrphanApproval letter

    To improve muscle strength in patients with Barth syndrome weighing at least 30 kg

  • Hernexeos (Zongertinib) · Boehringer IngelheimAug 8, 2025
    Original approval · NDA 219042NovelBreakthrough therapyAccelerated approvalPriority reviewApproval letter

    To treat adults with unresectable or metastatic non-squamous non-small cell lung cancer whose tumors have HER2 tyrosine kinase domain activating mutations, as detected by an FDA-approved test, and who have received prior systemic therapy

  • Modeyso (Dordaviprone Hydrochloride) · ChimerixAug 6, 2025
    Original approval · NDA 219876NovelAccelerated approvalPriority reviewOrphanApproval letter

    To treat diffuse midline glioma harboring an H3 K27M mutation with progressive disease following prior therapy

  • Lynozyfic (Linvoseltamab-Gcpt) · Rengeneron Pharmaceuticals, Inc.Jul 2, 2025
    Original approval · BLA 761400NovelAccelerated approvalPriority reviewOrphanApproval letter

    To treat relapsed or refractory multiple myeloma after at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti CD38 monoclonal antibody

  • Zegfrovy (Sunvozertinib) · DizalJul 2, 2025
    Original approval · NDA 219839NovelBreakthrough therapyAccelerated approvalPriority reviewApproval letter

    To treat locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations, as detected by an FDA-approved test, with disease progression on or after platinum-based chemotherapy

  • Datroway (Datopotamab Deruxtecan-Dlnk) · Daiichi Sankyo INCJun 23, 2025
    Original approval · BLA 761464NovelBreakthrough therapyAccelerated approvalPriority reviewApproval letter
  • Brukinsa (Zanubrutinib) · Beone Medicines USAJun 10, 2025
    Original approval · NDA 218785Accelerated approvalOrphanApproval letter
  • Emrelis (Telisotuzumab Vedotin-Tllv) · Abbvie INCMay 14, 2025
    Original approval · BLA 761384NovelBreakthrough therapyAccelerated approvalPriority reviewApproval letter

    To treat locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression after prior systemic therapy

  • Avmapki Fakzynja CO-Pack (Copackaged) (Avutometinib Potassium, Defactinib Hydrochloride) · Verastem INCMay 8, 2025
    Original approval · NDA 219616NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter

    To treat KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) after prior systemic therapy

  • Vanrafia (Atrasentan Hydrochloride) · NovartisApr 2, 2025
    Original approval · NDA 219208NovelAccelerated approvalApproval letter

    To reduce proteinuria in adults with primary immunoglobulin A nephropathy at risk of rapid disease progression

  • Opdivo Qvantig (Nivolumab, Hyaluronidase-Nvhy) · Bristol-Myers SquibbDec 27, 2024
    Original approval · BLA 761381Accelerated approvalApproval letter
  • Bizengri (Zenocutuzumab-Zbco) · Merus N.V.Dec 4, 2024
    Original approval · BLA 761352NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter

    To treat non-small cell lung cancer and pancreatic adenocarcinoma

  • Ziihera (Zanidatamab-Hrii) · Jazz PharmsNov 20, 2024
    Original approval · BLA 761416NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter

    To treat unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer

  • Livdelzi (Seladelpar Lysine) · Gilead Sciences INCAug 14, 2024
    Original approval · NDA 217899NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter

    To treat primary biliary cholangitis (PBC)

  • Krazati (Adagrasib) · BristolJun 21, 2024
    Efficacy supplement 5 · NDA 216340Breakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter
  • Iqirvo (Elafibranor) · IpsenJun 10, 2024
    Original approval · NDA 218860NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter

    To treat primary biliary cholangitis in combination with ursodeoxycholic acid

  • Retevmo (Selpercatinib) · Eli Lilly and COMay 29, 2024
    Efficacy supplement 12 · NDA 213246Accelerated approvalPriority reviewOrphanApproval letter
  • Imdelltra (Tarlatamab-Dlle) · Amgen INCMay 16, 2024
    Original approval · BLA 761344NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter

    To treat extensive stage small cell lung cancer

  • Ojemda (Tovorafenib) · Day One BiopharmsApr 23, 2024
    Original approval · NDA 217700NovelAccelerated approvalPriority reviewOrphanApproval letter
  • Ojemda (Tovorafenib) · Day One BiopharmsApr 23, 2024
    Original approval · NDA 218033NovelAccelerated approvalPriority reviewOrphanApproval letter

    To treat relapsed or refractory pediatric low-grade glioma

  • Rezdiffra (Resmetirom) · MadrigalMar 14, 2024
    Original approval · NDA 217785NovelBreakthrough therapyAccelerated approvalPriority reviewApproval letter

    To treat noncirrhotic non-alcoholic steatohepatitis with moderate to advanced liver scarring

  • Fabhalta (Iptacopan Hydrochloride) · NovartisDec 5, 2023
    Original approval · NDA 218276NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter

    To treat paroxysmal nocturnal hemoglobinuria

  • Augtyro (Repotrectinib) · BristolNov 15, 2023
    Original approval · NDA 218213NovelAccelerated approvalPriority reviewOrphanApproval letter

    To treat ROS1-positive non-small cell lung cancer

  • Rozlytrek (Entrectinib) · Genentech INCOct 20, 2023
    Original approval · NDA 218550Accelerated approvalPriority reviewOrphanApproval letter
  • Elrexfio (Elranatamab) · Pfizer INCAug 14, 2023
    Original approval · BLA 761345NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter

    To treat adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy

  • Talvey (Talquetamab-Tgvs) · Janssen BiotechAug 9, 2023
    Original approval · BLA 761342NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter

    To treat adults with relapsed or refractory multiple myeloma who have received at least four prior therapies

  • Columvi (Glofitamab-Gxbm) · Genentech INCJun 15, 2023
    Original approval · BLA 761309NovelAccelerated approvalPriority reviewApproval letter

    To treat diffuse large B-cell lymphoma, not otherwise specified, or large B-cell lymphoma arising from follicular lymphoma after two or more lines of systemic therapy

  • Epkinly (Epcoritamab-Bysp) · Genmab US, Inc.May 19, 2023
    Original approval · BLA 761324NovelAccelerated approvalPriority reviewOrphanApproval letter

    To treat relapsed or refractory diffuse large B-cell lymphoma (not otherwise specified) and high-grade B-cell lymphoma after two or more lines of systemic therapy

  • Qalsody (Tofersen) · Biogen MaApr 25, 2023
    Original approval · NDA 215887NovelAccelerated approvalPriority reviewOrphanApproval letter

    To treat amyotrophic lateral sclerosis in adults who have a SOD1 gene mutation

  • Zynyz (Retifanlimab-Dlwr) · Incyte CorpMar 22, 2023
    Original approval · BLA 761334NovelAccelerated approvalPriority reviewOrphanApproval letter

    To treat metastatic or recurrent locally advanced Merkel cell carcinoma

  • Filspari (Sparsentan) · TravereFeb 17, 2023
    Original approval · NDA 216403NovelAccelerated approvalPriority reviewOrphanApproval letter

    To reduce proteinuria in adults with primary immunoglobulin A nephropathy at risk of rapid disease progression

  • Jaypirca (Pirtobrutinib) · Loxo OncolJan 27, 2023
    Original approval · NDA 216059NovelAccelerated approvalPriority reviewOrphanApproval letter

    To treat relapsed or refractory mantle cell lymphoma in adults who have had at least two lines of systemic therapy, including a BTK inhibitor

  • Leqembi (Lecanemab-Irmb) · Eisai INCJan 6, 2023
    Original approval · BLA 761269NovelBreakthrough therapyAccelerated approvalPriority reviewApproval letter

    To treat Alzheimer's disease

  • Lunsumio Velo (Mosunetuzumab-Axgb) · Genentech INCDec 22, 2022
    Original approval · BLA 761263NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter

    To treat adults with relapsed or refractory follicular lymphoma, a type of non-Hodgkin lymphoma

  • Krazati (Adagrasib) · BristolDec 12, 2022
    Original approval · NDA 216340NovelBreakthrough therapyAccelerated approvalOrphanApproval letter

    To treat KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer in adults who have received at least one prior systemic therapy

  • Tzield (Teplizumab-Mzwv) · Provention Bio INCNov 17, 2022
    Original approval · BLA 761183NovelBreakthrough therapyAccelerated approvalPriority reviewApproval letter
  • Elahere (Mirvetuximab Soravtansine-Gynx) · Immunogen INCNov 14, 2022
    Original approval · BLA 761310NovelAccelerated approvalPriority reviewOrphanApproval letter

    To treat patients with recurrent ovarian cancer that is resistant to platinum therapy

  • Tecvayli (Teclistamab-Cqyv) · Janssen BiotechOct 25, 2022
    Original approval · BLA 761291NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter

    To treat relapsed or refractory multiple myeloma among adults who have received at least four specific lines of therapy

  • Lytgobi (Futibatinib) · Taiho OncologySep 30, 2022
    Original approval · NDA 214801NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter

    To treat intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements

  • Calquence (Acalabrutinib Maleate) · AstrazenecaAug 3, 2022
    Original approval · NDA 216387Accelerated approvalOrphan
  • Vijoice (Alpelisib) · NovartisApr 5, 2022
    Original approval · NDA 215039NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter
  • Vonjo (Pacritinib Citrate) · SobiFeb 28, 2022
    Original approval · NDA 208712NovelAccelerated approvalPriority reviewOrphanApproval letter

    To treat intermediate or high-risk primary or secondary myelofibrosis in adults with low platelets

Page 1 of 4Older

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.